InMed Pharmaceuticals Files Q1 2025 10-Q
Ticker: INM · Form: 10-Q · Filed: May 12, 2025 · CIK: 1728328
Sentiment: neutral
Topics: 10-Q, quarterly-report, pharmaceuticals
TL;DR
InMed Pharma filed its 10-Q for Q1 2025. All systems go.
AI Summary
InMed Pharmaceuticals Inc. filed its quarterly report for the period ending March 31, 2025. The company, incorporated in British Columbia, Canada, operates in the pharmaceutical preparations sector. Its principal executive offices are located in Vancouver, BC.
Why It Matters
This filing provides investors with an update on InMed Pharmaceuticals' financial performance and operational status for the first quarter of fiscal year 2025.
Risk Assessment
Risk Level: low — This is a standard quarterly filing providing routine financial and operational updates.
Key Players & Entities
- InMed Pharmaceuticals Inc. (company) — Registrant
- March 31, 2025 (date) — Quarterly period end date
- Vancouver, BC (location) — Principal executive offices location
- 001-39685 (other) — Commission File Number
FAQ
What is the primary business of InMed Pharmaceuticals Inc.?
InMed Pharmaceuticals Inc. is primarily involved in the Pharmaceutical Preparations industry, as indicated by its SIC code 2834.
When is the fiscal year end for InMed Pharmaceuticals Inc.?
The fiscal year end for InMed Pharmaceuticals Inc. is June 30.
Where are InMed Pharmaceuticals Inc.'s principal executive offices located?
The principal executive offices of InMed Pharmaceuticals Inc. are located at Suite 1445 - 885 W. Georgia Street, Vancouver, B.C., Canada, V6C 3E8.
What is the Commission File Number for InMed Pharmaceuticals Inc.?
The Commission File Number for InMed Pharmaceuticals Inc. is 001-39685.
What type of report is this filing?
This filing is a Form 10-Q, which is a quarterly report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding InMed Pharmaceuticals Inc. (INM).